Shorts ga­lore: Mud­dy Wa­ters sees slide for Pep­tiDream, tweets con­cerns about Fi­bro­Gen's new da­ta

The short sell­er Mud­dy Wa­ters is tak­ing aim at Japan’s most prof­itable biotech, pro­ject­ing a slide for a com­pa­ny that has sky­rock­et­ed over the last four years. Mean­while, the firm tweet­ed out an analy­sis ac­cus­ing Fi­bro­Gen of ma­nip­u­lat­ing da­ta to ob­scure safe­ty con­cerns in their lat­est re­veal, al­though some in­vestors seem sat­is­fied by the biotech’s ex­pla­na­tion.

Mud­dy Wa­ters short­ed Pep­tiDream, a Japan­ese biotech-for-hire that lever­aged its pep­tide li­brary in­to part­ner­ships with some of the world’s largest phar­ma­ceu­ti­cal com­pa­nies, a 50% prof­it mar­gin and $6 bil­lion val­u­a­tion. The firm not­ed that de­spite its es­teem, Pep­tiDream has failed to bring a drug to mar­ket 13 years af­ter its 2006 launch (al­though this is not es­pe­cial­ly rare for biotech).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER